Medicure Obtains Exclusive License for Cardiovascular Drug

Pharmaceutical Investing

Medicure announced its subsidiary Medicure International it acquired the exclusive licensing rights of an undisclosed recently approved cardiovascular drug in the US.

Medicure (TSXV:MPH; OTC:MCUJF) announced its subsidiary Medicure International it acquired the exclusive licensing rights of an undisclosed recently approved cardiovascular drug in the US.
As quoted in the press release:

The licensing agreement is for a term of seven years with extensions to the term available.

The cardiovascular drug was approved earlier in 2017 by the U.S. Food and Drug Administration (“FDA”) for sale and marketing in the United States and the Company intends to launch the product using its existing commercial sales force and infrastructure with a target commercial launch date in the first half of 2018.

“This licensing agreement, similar to our recent licensing of PREXXARTAN, fits well with Medicure’s mission of being a significant cardiovascular pharmaceutical company focused on the U.S. market,” commented Medicure’s President and CEO, Dr. Albert D. Friesen.

Click here to read the full press release.